{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T21:35:37Z","timestamp":1790026537295,"version":"4.0.1"},"reference-count":73,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T00:00:00Z","timestamp":1785196800000},"content-version":"vor","delay-in-days":20,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82350128"],"award-info":[{"award-number":["82350128"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-026-73683-z","type":"journal-article","created":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T12:27:57Z","timestamp":1783513677000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["SBRT embedded in low-dose RT plus \u03b1PD-1 (immuno-EclipseRT, iERT) elicits CD8+ T cell immunity against bulky tumors via an IFN-I\/NK\/DC axis"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9508-5497","authenticated-orcid":false,"given":"Ren","family":"Luo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8978-892X","authenticated-orcid":false,"given":"Min","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7936-8569","authenticated-orcid":false,"given":"Kai","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-1281-8317","authenticated-orcid":false,"given":"Yufeng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanghai","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuoran","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zichong","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuanwei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuangsi","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhou","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linglu","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhao","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guo","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3061-2473","authenticated-orcid":false,"given":"Ruizhan","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feifei","family":"Na","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youling","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meijuan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingwen","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Long","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renming","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Di","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1710-0975","authenticated-orcid":false,"given":"Gabriele","family":"Niedermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4501-7538","authenticated-orcid":false,"given":"Jianxin","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1671-1408","authenticated-orcid":false,"given":"You","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,8]]},"reference":[{"key":"73683_CR1","doi-asserted-by":"publisher","first-page":"e352","DOI":"10.1016\/S1470-2045(24)00075-5","volume":"25","author":"C Lynch","year":"2024","unstructured":"Lynch, C., Pitroda, S. P. & Weichselbaum, R. R. Radiotherapy, immunity, and immune checkpoint inhibitors.  Lancet Oncol. 25, e352\u2013e362 (2024).","journal-title":"Lancet Oncol."},{"key":"73683_CR2","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/s41571-023-00782-x","volume":"20","author":"L Galluzzi","year":"2023","unstructured":"Galluzzi, L., Aryankalayil, M. J., Coleman, C. N. & Formenti, S. C. Emerging evidence for adapting radiotherapy to immunotherapy. Nat. Rev. Clin. Oncol. 20, 543\u2013557 (2023).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"73683_CR3","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/S1470-2045(20)30737-3","volume":"22","author":"NY Lee","year":"2021","unstructured":"Lee, N. Y. et al. Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial.  Lancet Oncol. 22, 450\u2013462 (2021).","journal-title":"Lancet Oncol."},{"key":"73683_CR4","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/S2213-2600(20)30391-X","volume":"9","author":"WSME Theelen","year":"2021","unstructured":"Theelen, W. S. M. E. et al. Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials. Lancet Respir. Med. 9, 467\u2013475 (2021).","journal-title":"Lancet Respir. Med."},{"key":"73683_CR5","doi-asserted-by":"crossref","unstructured":"Bradley, J. D. et al. LBA1 Durvalumab in combination with chemoradiotherapy for patients with unresectable stage III NSCLC: Final results from PACIFIC-2. ESMO Open 9, 102986 (2024).","DOI":"10.1016\/j.esmoop.2024.102986"},{"key":"73683_CR6","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1093\/neuonc\/noac116","volume":"24","author":"M Lim","year":"2022","unstructured":"Lim, M. et al. Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter. Neuro Oncol. 24, 1935\u20131949 (2022).","journal-title":"Neuro Oncol."},{"key":"73683_CR7","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/nature22079","volume":"545","author":"AC Huang","year":"2017","unstructured":"Huang, A. C. et al. T-cell invigoration to tumour burden ratio associated with anti-PD-1 response. Nature 545, 60\u201365 (2017).","journal-title":"Nature"},{"key":"73683_CR8","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/s41591-018-0014-x","volume":"24","author":"M Binnewies","year":"2018","unstructured":"Binnewies, M. et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat. Med. 24, 541\u2013550 (2018).","journal-title":"Nat. Med."},{"key":"73683_CR9","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1001\/jamaoncol.2022.7711","volume":"9","author":"MA Socinski","year":"2023","unstructured":"Socinski, M. A. et al. Association of immune-related adverse events with efficacy of atezolizumab in patients with non-small cell lung cancer: pooled analyses of the phase 3 IMpower130, IMpower132, and IMpower150 randomized clinical trials. JAMA Oncol. 9, 527\u2013535 (2023).","journal-title":"JAMA Oncol."},{"key":"73683_CR10","doi-asserted-by":"publisher","unstructured":"Beck, M. et al. Differences and similarities in the pattern of early metabolic and morphologic response after induction chemo-immunotherapy versus induction chemotherapy alone in locally advanced squamous cell head and neck cancer. Cancers 14, https:\/\/doi.org\/10.3390\/cancers14194811 (2022).","DOI":"10.3390\/cancers14194811"},{"key":"73683_CR11","doi-asserted-by":"publisher","first-page":"2223","DOI":"10.3390\/cancers15082223","volume":"15","author":"J Grambow-Velilla","year":"2023","unstructured":"Grambow-Velilla, J. et al. Total metabolic tumor volume on 18F-FDG PET\/CT is a useful prognostic biomarker for patients with extensive small-cell lung cancer undergoing first-line chemo-immunotherapy. Cancers 15, 2223 (2023).","journal-title":"Cancers"},{"key":"73683_CR12","doi-asserted-by":"publisher","first-page":"629722","DOI":"10.3389\/fimmu.2020.629722","volume":"11","author":"SI Kim","year":"2020","unstructured":"Kim, S. I., Cassella, C. R. & Byrne, K. T. Tumor burden and immunotherapy: impact on immune infiltration and therapeutic outcomes. Front. Immunol. 11, 629722 (2020).","journal-title":"Front. Immunol."},{"key":"73683_CR13","doi-asserted-by":"publisher","first-page":"442","DOI":"10.2174\/156652409788167087","volume":"9","author":"S Rockwell","year":"2009","unstructured":"Rockwell, S., Dobrucki, I. T., Kim, E. Y., Marrison, S. T. & Vu, V. T. Hypoxia and radiation therapy: past history, ongoing research, and future promise. Curr. Mol. Med. 9, 442\u2013458 (2009).","journal-title":"Curr. Mol. Med."},{"key":"73683_CR14","doi-asserted-by":"publisher","first-page":"4833","DOI":"10.1200\/JCO.2006.07.5937","volume":"24","author":"R Timmerman","year":"2006","unstructured":"Timmerman, R. et al. Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. J. Clin. Oncol. 24, 4833\u20134839 (2006).","journal-title":"J. Clin. Oncol."},{"key":"73683_CR15","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1016\/j.jtho.2017.04.007","volume":"12","author":"D Przybysz","year":"2017","unstructured":"Przybysz, D. & Bradley, J. D. Challenging situations for lung SBRT. J. Thorac. Oncol. 12, 916\u2013918 (2017).","journal-title":"J. Thorac. Oncol."},{"key":"73683_CR16","doi-asserted-by":"crossref","unstructured":"Dawson, L. A., Hashem, S. & Bujold, A. Stereotactic body radiation therapy for hepatocellular carcinoma. in American Society of Clinical Oncology Educational Book (2012).","DOI":"10.14694\/EdBook_AM.2012.32.171"},{"key":"73683_CR17","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ijrobp.2019.02.047","volume":"110","author":"CW Song","year":"2021","unstructured":"Song, C. W. et al. Biological principles of stereotactic body radiation therapy (SBRT) and stereotactic radiation surgery (SRS): indirect cell death. Int. J. Radiat. Oncol. Biol. Phys. 110, 21\u201334 (2021).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"73683_CR18","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1056\/NEJMra1608986","volume":"377","author":"DE Citrin","year":"2017","unstructured":"Citrin, D. E. Recent developments in radiotherapy. N. Engl. J. Med. 377, 1065\u20131075 (2017).","journal-title":"N. Engl. J. Med."},{"key":"73683_CR19","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1084\/jem.20050915","volume":"202","author":"N Casares","year":"2005","unstructured":"Casares, N. et al. Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J. Exp. Med. 202, 1691\u20131701 (2005).","journal-title":"J. Exp. Med."},{"key":"73683_CR20","doi-asserted-by":"publisher","first-page":"e28518","DOI":"10.4161\/onci.28518","volume":"3","author":"EB Golden","year":"2014","unstructured":"Golden, E. B. et al. Radiation fosters dose-dependent and chemotherapy-induced immunogenic cell death. Oncoimmunology 3, e28518 (2014).","journal-title":"Oncoimmunology"},{"key":"73683_CR21","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/nrc.2018.6","volume":"18","author":"W Ngwa","year":"2018","unstructured":"Ngwa, W. et al. Using immunotherapy to boost the abscopal effect. Nat. Rev. Cancer 18, 313\u2013322 (2018).","journal-title":"Nat. Rev. Cancer"},{"key":"73683_CR22","doi-asserted-by":"publisher","first-page":"e000867","DOI":"10.1136\/jitc-2020-000867","volume":"8","author":"ZS Buchwald","year":"2020","unstructured":"Buchwald, Z. S. et al. Tumor-draining lymph node is important for a robust abscopal effect stimulated by radiotherapy. J. Immunother. Cancer 8, e000867 (2020).","journal-title":"J. Immunother. Cancer"},{"key":"73683_CR23","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/S0140-6736(23)01384-3","volume":"402","author":"JY Chang","year":"2023","unstructured":"Chang, J. Y. et al. Stereotactic ablative radiotherapy with or without immunotherapy for early-stage or isolated lung parenchymal recurrent node-negative non-small-cell lung cancer: an open-label, randomised, phase 2 trial. Lancet 402, 871\u2013881 (2023).","journal-title":"Lancet"},{"key":"73683_CR24","doi-asserted-by":"publisher","first-page":"e434","DOI":"10.1016\/S1470-2045(19)30157-3","volume":"20","author":"SP Pitroda","year":"2019","unstructured":"Pitroda, S. P., Chmura, S. J. & Weichselbaum, R. R. Integration of radiotherapy and immunotherapy for treatment of oligometastases.  Lancet Oncol. 20, e434\u2013e442 (2019).","journal-title":"Lancet Oncol."},{"key":"73683_CR25","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1016\/j.ijrobp.2016.03.024","volume":"95","author":"J Zhao","year":"2016","unstructured":"Zhao, J. et al. Simple factors associated with radiation-induced lung toxicity after stereotactic body radiation therapy of the thorax: a pooled analysis of 88 studies. Int. J. Radiat. Oncol. Biol. Phys. 95, 1357\u20131366 (2016).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"73683_CR26","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.prro.2017.04.014","volume":"7","author":"GMM Videtic","year":"2017","unstructured":"Videtic, G. M. M. et al. Stereotactic body radiation therapy for early-stage non-small cell lung cancer: executive summary of an ASTRO evidence-based guideline. Pr. Radiat. Oncol. 7, 295\u2013301 (2017).","journal-title":"Pr. Radiat. Oncol."},{"key":"73683_CR27","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.ccr.2013.09.014","volume":"24","author":"F Klug","year":"2013","unstructured":"Klug, F. et al. Low-dose irradiation programs macrophage differentiation to an iNOS + \/M1 phenotype that orchestrates effective T cell immunotherapy. Cancer Cell 24, 589\u2013602 (2013).","journal-title":"Cancer Cell"},{"key":"73683_CR28","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.ijrobp.2020.05.002","volume":"108","author":"L Yin","year":"2020","unstructured":"Yin, L. et al. Effect of low-dose radiation therapy on abscopal responses to hypofractionated radiation therapy and anti-PD1 in mice and patients with non-small cell lung cancer. Int. J. Radiat. Oncol. Biol. Phys. 108, 212\u2013224 (2020).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"73683_CR29","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000537","volume":"8","author":"HB Barsoumian","year":"2020","unstructured":"Barsoumian, H. B. et al. Low-dose radiation treatment enhances systemic antitumor immune responses by overcoming the inhibitory stroma. J. Immunother. Cancer 8, e000537 (2020).","journal-title":"J. Immunother. Cancer"},{"key":"73683_CR30","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1158\/2159-8290.CD-21-0003","volume":"12","author":"FG Herrera","year":"2022","unstructured":"Herrera, F. G. et al. Low-dose radiotherapy reverses tumor immune desertification and resistance to immunotherapy. Cancer Discov. 12, 108\u2013133 (2022).","journal-title":"Cancer Discov."},{"key":"73683_CR31","doi-asserted-by":"publisher","first-page":"4098","DOI":"10.1158\/1078-0432.CCR-23-0315","volume":"29","author":"X Zhou","year":"2023","unstructured":"Zhou, X. et al. Safety and tolerability of low-dose radiation and stereotactic body radiotherapy + sintilimab for treatment-na\u00efve stage IV PD-L1+ non-small cell lung cancer patients. Clin. Cancer Res. 29, 4098\u20134108 (2023).","journal-title":"Clin. Cancer Res."},{"key":"73683_CR32","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1016\/j.ijrobp.2020.03.028","volume":"107","author":"RJ Griffin","year":"2020","unstructured":"Griffin, R. J. et al. Understanding high-dose, ultra-high dose rate, and spatially fractionated radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 107, 766\u2013778 (2020).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"73683_CR33","first-page":"100569","volume":"39","author":"F Iori","year":"2023","unstructured":"Iori, F. et al. Lattice radiation therapy in clinical practice: A systematic review. Clin. Transl. Radiat. Oncol. 39, 100569 (2023).","journal-title":"Clin. Transl. Radiat. Oncol."},{"key":"73683_CR34","doi-asserted-by":"publisher","DOI":"10.1186\/s13014-019-1227-y","volume":"14","author":"S Tubin","year":"2019","unstructured":"Tubin, S., Popper, H. H. & Brcic, L. Novel stereotactic body radiation therapy (SBRT)-based partial tumor irradiation targeting hypoxic segment of bulky tumors (SBRT-PATHY): improvement of the radiotherapy outcome by exploiting the bystander and abscopal effects. Radiat. Oncol. 14, 21 (2019).","journal-title":"Radiat. Oncol."},{"key":"73683_CR35","doi-asserted-by":"publisher","first-page":"eadk0642","DOI":"10.1126\/scitranslmed.adk0642","volume":"16","author":"JC Jagodinsky","year":"2024","unstructured":"Jagodinsky, J. C. et al. Intratumoral radiation dose heterogeneity augments antitumor immunity in mice and primes responses to checkpoint blockade. Sci. Transl. Med. 16, eadk0642 (2024).","journal-title":"Sci. Transl. Med."},{"key":"73683_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-53015-9","volume":"15","author":"P Bergeron","year":"2024","unstructured":"Bergeron, P. et al. Non-homogenous intratumor ionizing radiation doses synergize with PD1 and CXCR2 blockade. Nat. Commun. 15, 8845 (2024).","journal-title":"Nat. Commun."},{"key":"73683_CR37","doi-asserted-by":"publisher","first-page":"S95","DOI":"10.1016\/j.ijrobp.2024.07.170","volume":"120","author":"R Luo","year":"2024","unstructured":"Luo, R. et al. The eclipse-radiotherapy combined with ICI orchestrates CD8 + T cell- and NK cell-dependent anti-tumor efficacy against bulky tumors. Int. J. Radiat. Oncol.*Biol.*Phys. 120, S95 (2024).","journal-title":"Int. J. Radiat. Oncol.*Biol.*Phys."},{"key":"73683_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms15618","volume":"8","author":"C Vanpouille-Box","year":"2017","unstructured":"Vanpouille-Box, C. et al. DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity. Nat. Commun. 8, 15618 (2017).","journal-title":"Nat. Commun."},{"key":"73683_CR39","doi-asserted-by":"publisher","first-page":"7243","DOI":"10.1158\/1078-0432.CCR-19-1344","volume":"25","author":"R Luo","year":"2019","unstructured":"Luo, R. et al. Cisplatin facilitates radiation-induced abscopal effects in conjunction with PD-1 checkpoint blockade through CXCR3\/CXCL10-mediated T-cell recruitment. Clin. Cancer Res. 25, 7243\u20137255 (2019).","journal-title":"Clin. Cancer Res."},{"key":"73683_CR40","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1158\/1078-0432.CCR-22-1591","volume":"29","author":"R Luo","year":"2023","unstructured":"Luo, R. et al. Necroptosis-dependent immunogenicity of cisplatin: implications for enhancing the radiation-induced abscopal effect. Clin. Cancer Res. 29, 667\u2013683 (2023).","journal-title":"Clin. Cancer Res."},{"key":"73683_CR41","doi-asserted-by":"publisher","unstructured":"Sitnikova, S. I. et al. Novel non-terminal tumor sampling procedure using fine needle aspiration supports immuno-oncology biomarker discovery in preclinical mouse models. J. Immunother. Cancer 9, https:\/\/doi.org\/10.1136\/jitc-2021-002894 (2021).","DOI":"10.1136\/jitc-2021-002894"},{"key":"73683_CR42","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/s41577-021-00558-3","volume":"22","author":"NK Bj\u00f6rkstr\u00f6m","year":"2022","unstructured":"Bj\u00f6rkstr\u00f6m, N. K., Strunz, B. & Ljunggren, H. G. Natural killer cells in antiviral immunity. Nat. Rev. Immunol. 22, 112\u2013123 (2022).","journal-title":"Nat. Rev. Immunol."},{"key":"73683_CR43","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-37825-x","volume":"14","author":"K Onyshchenko","year":"2023","unstructured":"Onyshchenko, K. et al. Expansion of circulating stem-like CD8(+) T cells by adding CD122-directed IL-2 complexes to radiation and anti-PD1 therapies in mice. Nat. Commun. 14, 2087 (2023).","journal-title":"Nat. Commun."},{"key":"73683_CR44","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1016\/j.cell.2024.02.005","volume":"187","author":"Y Wu","year":"2024","unstructured":"Wu, Y. et al. Neutrophil profiling illuminates anti-tumor antigen-presenting potency. Cell 187, 1422\u20131439 (2024).","journal-title":"Cell"},{"key":"73683_CR45","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/s41586-023-06816-9","volume":"625","author":"A Cui","year":"2024","unstructured":"Cui, A. et al. Dictionary of immune responses to cytokines at single-cell resolution. Nature 625, 377\u2013384 (2024).","journal-title":"Nature"},{"key":"73683_CR46","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1016\/j.cell.2018.01.004","volume":"172","author":"JP B\u00f6ttcher","year":"2018","unstructured":"B\u00f6ttcher, J. P. et al. NK Cells stimulate recruitment of cDC1 into the tumor microenvironment promoting cancer immune control. Cell 172, 1022\u20131037 (2018).","journal-title":"Cell"},{"key":"73683_CR47","doi-asserted-by":"publisher","first-page":"41128","DOI":"10.1074\/jbc.M206747200","volume":"277","author":"C Luberto","year":"2002","unstructured":"Luberto, C. et al. Inhibition of tumor necrosis factor-induced cell death in MCF7 by a novel inhibitor of neutral sphingomyelinase. J. Biol. Chem. 277, 41128\u201341139 (2002).","journal-title":"J. Biol. Chem."},{"key":"73683_CR48","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1016\/S1074-7613(00)80447-1","volume":"6","author":"A Porgador","year":"1997","unstructured":"Porgador, A., Yewdell, J. W., Deng, Y., Bennink, J. R. & Germain, R. N. Localization, quantitation, and in situ detection of specific peptide-MHC class I complexes using a monoclonal antibody. Immunity 6, 715\u2013726 (1997).","journal-title":"Immunity"},{"key":"73683_CR49","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1146\/annurev-med-012017-043208","volume":"69","author":"M Hashimoto","year":"2018","unstructured":"Hashimoto, M. et al. CD8 T Cell exhaustion in chronic infection and cancer: opportunities for interventions. Annu. Rev. Med. 69, 301\u2013318 (2018).","journal-title":"Annu. Rev. Med."},{"key":"73683_CR50","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/nature19330","volume":"537","author":"SJ Im","year":"2016","unstructured":"Im, S. J. et al. Defining CD8\u2009+\u2009T cells that provide the proliferative burst after PD-1 therapy. Nature 537, 417\u2013421 (2016).","journal-title":"Nature"},{"key":"73683_CR51","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.immuni.2018.12.021","volume":"50","author":"I Siddiqui","year":"2019","unstructured":"Siddiqui, I. et al. Intratumoral Tcf1+PD-1\u2009+\u2009CD8\u2009+\u2009T cells with stem-like properties promote tumor control in response to vaccination and checkpoint blockade immunotherapy. Immunity 50, 195\u2013211 (2019).","journal-title":"Immunity"},{"key":"73683_CR52","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1038\/s41590-019-0312-6","volume":"20","author":"BC Miller","year":"2019","unstructured":"Miller, B. C. et al. Subsets of exhausted CD8(+) T cells differentially mediate tumor control and respond to checkpoint blockade. Nat. Immunol. 20, 326\u2013336 (2019).","journal-title":"Nat. Immunol."},{"key":"73683_CR53","doi-asserted-by":"publisher","first-page":"9730","DOI":"10.1073\/pnas.93.18.9730","volume":"93","author":"AY Huang","year":"1996","unstructured":"Huang, A. Y. et al. The immunodominant major histocompatibility complex class I-restricted antigen of a murine colon tumor derives from an endogenous retroviral gene product. Proc. Natl. Acad. Sci. USA 93, 9730\u20139735 (1996).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"73683_CR54","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.immuni.2022.12.002","volume":"56","author":"N Prokhnevska","year":"2023","unstructured":"Prokhnevska, N. et al. CD8(+) T cell activation in cancer comprises an initial activation phase in lymph nodes followed by effector differentiation within the tumor. Immunity 56, 107\u2013124 (2023).","journal-title":"Immunity"},{"key":"73683_CR55","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/s41571-021-00564-3","volume":"19","author":"FG Dall\u2019Olio","year":"2022","unstructured":"Dall\u2019Olio, F. G. et al. Tumour burden and efficacy of immune-checkpoint inhibitors. Nat. Rev. Clin. Oncol. 19, 75\u201390 (2022).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"73683_CR56","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/j.ccell.2021.02.013","volume":"39","author":"DA Braun","year":"2021","unstructured":"Braun, D. A. et al. Progressive immune dysfunction with advancing disease stage in renal cell carcinoma. Cancer Cell 39, 632\u2013648 (2021).","journal-title":"Cancer Cell"},{"key":"73683_CR57","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1038\/s41586-023-05912-0","volume":"616","author":"S Sen Santara","year":"2023","unstructured":"Sen Santara, S. et al. The NK cell receptor NKp46 recognizes ecto-calreticulin on ER-stressed cells. Nature 616, 348\u2013356 (2023).","journal-title":"Nature"},{"key":"73683_CR58","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.radonc.2020.09.052","volume":"154","author":"D Yan","year":"2021","unstructured":"Yan, D. et al. Inter\/intra-tumoral dose response variations assessed using FDG-PET\/CT feedback images: Impact on tumor control and treatment dose prescription. Radiother. Oncol. 154, 235\u2013242 (2021).","journal-title":"Radiother. Oncol."},{"key":"73683_CR59","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/nri2216","volume":"8","author":"L Zitvogel","year":"2008","unstructured":"Zitvogel, L., Apetoh, L., Ghiringhelli, F. & Kroemer, G. Immunological aspects of cancer chemotherapy. Nat. Rev. Immunol. 8, 59\u201373 (2008).","journal-title":"Nat. Rev. Immunol."},{"key":"73683_CR60","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1084\/jem.20101158","volume":"208","author":"MS Diamond","year":"2011","unstructured":"Diamond, M. S. et al. Type I interferon is selectively required by dendritic cells for immune rejection of tumors. J. Exp. Med. 208, 1989\u20132003 (2011).","journal-title":"J. Exp. Med."},{"key":"73683_CR61","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/j.immuni.2014.10.019","volume":"41","author":"L Deng","year":"2014","unstructured":"Deng, L. et al. STING-Dependent cytosolic DNA sensing promotes radiation-induced type I interferon-dependent antitumor immunity in immunogenic tumors. Immunity 41, 843\u2013852 (2014).","journal-title":"Immunity"},{"key":"73683_CR62","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1158\/2326-6066.CIR-19-0449","volume":"8","author":"E Wennerberg","year":"2020","unstructured":"Wennerberg, E. et al. CD73 Blockade promotes dendritic cell infiltration of irradiated tumors and tumor rejection. Cancer Immunol. Res. 8, 465\u2013478 (2020).","journal-title":"Cancer Immunol. Res."},{"key":"73683_CR63","doi-asserted-by":"crossref","unstructured":"Mathieu, M. et al. Activation of sting in response to partial-tumor radiation exposure. Int. J. Radiat. Oncol. Biol. Phys. 117, 955\u2013965 (2023).","DOI":"10.1016\/j.ijrobp.2023.05.032"},{"key":"73683_CR64","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1016\/j.trecan.2022.04.003","volume":"8","author":"KA Tooley","year":"2022","unstructured":"Tooley, K. A., Escobar, G. & Anderson, A. C. Spatial determinants of CD8(+) T cell differentiation in cancer. Trends Cancer 8, 642\u2013654 (2022).","journal-title":"Trends Cancer"},{"key":"73683_CR65","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1200\/JCO.2017.76.2229","volume":"36","author":"JJ Luke","year":"2018","unstructured":"Luke, J. J. et al. Safety and clinical activity of pembrolizumab and multisite stereotactic body radiotherapy in patients with advanced solid tumors. J. Clin. Oncol. 36, 1611\u20131618 (2018).","journal-title":"J. Clin. Oncol."},{"key":"73683_CR66","doi-asserted-by":"publisher","first-page":"e162260","DOI":"10.1172\/JCI162260","volume":"133","author":"MC Korpics","year":"2023","unstructured":"Korpics, M. C. et al. Partial tumor irradiation plus pembrolizumab in treating large advanced solid tumor metastases. J. Clin. Invest. 133, e162260 (2023).","journal-title":"J. Clin. Invest."},{"key":"73683_CR67","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-32567-8","volume":"13","author":"RM Zemek","year":"2022","unstructured":"Zemek, R. M. et al. Temporally restricted activation of IFN\u03b2 signaling underlies response to immune checkpoint therapy in mice. Nat. Commun. 13, 4895 (2022).","journal-title":"Nat. Commun."},{"key":"73683_CR68","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1038\/s41568-024-00699-2","volume":"24","author":"RM Zemek","year":"2024","unstructured":"Zemek, R. M., Anagnostou, V., Pires da Silva, I., Long, G. V. & Lesterhuis, W. J. Exploiting temporal aspects of cancer immunotherapy. Nat. Rev. Cancer 24, 480\u2013497 (2024).","journal-title":"Nat. Rev. Cancer"},{"key":"73683_CR69","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-17204-5","volume":"7","author":"P Bankhead","year":"2017","unstructured":"Bankhead, P. et al. QuPath: Open source software for digital pathology image analysis. Sci. Rep. 7, 16878 (2017).","journal-title":"Sci. Rep."},{"key":"73683_CR70","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.celrep.2016.12.019","volume":"18","author":"P Charoentong","year":"2017","unstructured":"Charoentong, P. et al. Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade. Cell Rep. 18, 248\u2013262 (2017).","journal-title":"Cell Rep."},{"key":"73683_CR71","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-14-7","volume":"14","author":"S H\u00e4nzelmann","year":"2013","unstructured":"H\u00e4nzelmann, S., Castelo, R. & Guinney, J. GSVA: gene set variation analysis for microarray and RNA-Seq data. BMC Bioinform. 14, 7 (2013).","journal-title":"BMC Bioinform."},{"key":"73683_CR72","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-38946-z","volume":"14","author":"J Schmidt","year":"2023","unstructured":"Schmidt, J. et al. Neoantigen-specific CD8 T cells with high structural avidity preferentially reside in and eliminate tumors. Nat. Commun. 14, 3188 (2023).","journal-title":"Nat. Commun."},{"key":"73683_CR73","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1038\/leu.2016.321","volume":"31","author":"IV Zvyagin","year":"2017","unstructured":"Zvyagin, I. V. et al. Tracking T-cell immune reconstitution after TCR\u03b1\u03b2\/CD19-depleted hematopoietic cells transplantation in children. Leukemia 31, 1145\u20131153 (2017).","journal-title":"Leukemia"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-73683-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-73683-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-73683-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T18:10:45Z","timestamp":1785521445000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-73683-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,8]]},"references-count":73,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["73683"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-73683-z","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,8]]},"assertion":[{"value":"6 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Y. Lu has an invited speaker\/project lead\/principal investigator role with Roche, AstraZeneca, BeiGene, and Hengrui Pharmaceuticals; and an invited speaker role with Pfizer, Merck Sharp & Dohme, and Bristol-Myers Squibb. The remaining authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"7568"}}